Abstract
Disulfiram and its primary metabolite diethyldithiocarbamate are effective mechanism-based inhibitors of cytochrome P-450 2E1 (CYP2E1)1 in vitro. Single-dose disulfiram diminishes CYP2E1 activity in vivo and has been used to identify CYP2E1 participation in human drug metabolism and prevent CYP2E1-mediated toxification. Specificity of single-dose disulfiram toward CYP2E1 in vivo, however, remains unknown. This investigation determined single-dose disulfiram effects on human CYP 2C9, 2C19, 2D6, and 3A4 activities in vivo. In four randomized crossover experiments, volunteers received isoform-selective probes (oral tolbutamide, mephenytoin, dextromethorphan, or i.v. midazolam) on two occasions, 10 h after oral disulfiram or after no pretreatment (controls). Plasma and/or urine parent and/or metabolite concentrations were measured by HPLC or gas chromatography-mass spectrometry. CYP2C9, 2C19, 2D6, and 3A4 activities were determined from the tolbutamide metabolic ratio, 4′-hydroxymephenytoin excretion, and dextromethorphan/dextrorphan ratios in urine and midazolam systemic clearance, respectively. Midazolam clearance (670 ± 190 versus 700 ± 240 ml/min, disulfiram versus controls), dextromethorphan/dextrorphan metabolic ratio (0.013 ± 0.033 versus 0.015 ± 0.035), 4′-hydroxymephenytoin excretion (122 ± 22 versus 128 ± 25 μmol), and tolbutamide metabolite excretion (577 ± 157 versus 610 ± 208 μmol) were not significantly altered by disulfiram pretreatment, although the tolbutamide metabolic ratio was slightly diminished after disulfiram (60 ± 17 versus 81 ± 40, p < .05). Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo. When single-dose disulfiram is used as an in vivo probe for P-450, inhibition of drug metabolism suggests selective involvement of CYP2E1. Single-dose disulfiram should not cause untoward drug interactions from inhibition of other P-450 isoforms.
Footnotes
-
Send reprint requests to: Evan D. Kharasch, Department of Anesthesiology, Box 356540, University of Washington, Seattle, WA 98195. E-mail: kharasch{at}u.washington.edu
-
Supported by National Institutes of Health Grants R01 GM48712, P01 GM32165, and M01 RR00037 to the University of Washington Clinical Research Center.
- Abbreviation used is::
- TTCA
- 2-thiothiazolidine-4-carboxylic acid
- Received December 18, 1998.
- Accepted February 23, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|